<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00177736</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#0505059</org_study_id>
    <nct_id>NCT00177736</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Parameters of Two Different Doses of Cefepime</brief_title>
  <official_title>Pharmacodynamic Parameters of Two Different Doses of Cefepime</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Elan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <brief_summary>
    <textblock>
      Pharmacokinetics is the study of the disposition of drugs in the body, while pharmacodynamics&#xD;
      considers the interaction of the drug at the site of infection over time. Mathematical models&#xD;
      of antibiotic pharmacodynamics are sometimes used to predict if antibiotic doses are&#xD;
      sufficient to treat infection with organisms of different minimal inhibitory concentrations&#xD;
      of the antibiotic. Based on these models, there has been speculation that the antibiotic&#xD;
      cefepime dosed at one gram every 12 hours, is insufficient to kill all organisms within the&#xD;
      &quot;susceptible&quot; range. This study of patients treated with cefepime will involve the collection&#xD;
      of blood to determine cefepime concentrations, and determine if those concentrations are&#xD;
      effective in killing the bacteria at the site of infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a non-interventional study in that the antibiotic and its dose will be chosen by&#xD;
      the treating team not the investigators. Patients on cefepime who have ventilator-associated&#xD;
      pneumonia or bacteremia will be invited to participate in the study. Blood samples will be&#xD;
      taken to determine the pharmacokinetic profile of the drug. Blood cultures will be repeated&#xD;
      in patients with bacteremia to determine clearance of infection. A mini-BAL will be repeated&#xD;
      in patients with ventilator-associated pneumonia to determine clearance of pneumonia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Infection</condition>
  <condition>Bacteremia</condition>
  <condition>Pneumonia</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults of at least 18 years of age or older&#xD;
&#xD;
          2. Culture proven ventilator associated pneumonia (VAP) or bacteremia caused by a&#xD;
             cefepime susceptible gram negative pathogen:&#xD;
&#xD;
               -  Bacteremia is defined as at least one positive blood culture&#xD;
&#xD;
               -  VAP is defined by at least 10,000 cfu/ml of an organism from a bronchoalveolar&#xD;
                  lavage sample&#xD;
&#xD;
          3. Cefepime therapy (1 or 2 grams intravenously [IV] every [q] 8 hours or q 12 hours)&#xD;
             initiated as part of standard of care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concomitant VAP or bacteremia with a cefepime resistant organism&#xD;
&#xD;
          2. Concomitant therapy with an antimicrobial agent active against gram negative bacilli&#xD;
             other than a single dose of aminoglycoside&#xD;
&#xD;
          3. Patients requiring surgical or interventional drainage of purulent collections&#xD;
&#xD;
          4. Pregnant or lactating women&#xD;
&#xD;
          5. Dialysis patients&#xD;
&#xD;
          6. Contraindication to blood sampling&#xD;
&#xD;
          7. Cystic fibrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L Paterson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>December 11, 2007</last_update_submitted>
  <last_update_submitted_qc>December 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2007</last_update_posted>
  <responsible_party>
    <name_title>David Paterson, MD</name_title>
    <organization>UPMC</organization>
  </responsible_party>
  <keyword>ventilator associated pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

